Radiation Dermatitis: A phase 1 randomized double blinded placebo controlled study of the safety and efficacy of a caffeine-based antifibrosis cream in patients with breast cancer undergoing radiation therapy (ReDCoAT Study)

Go Back to All Clinical Trials

Radiation Dermatitis: A phase 1 randomized double blinded placebo controlled study of the safety and efficacy of a caffeine-based antifibrosis cream in patients with breast cancer undergoing radiation therapy (ReDCoAT Study)

Brief description of study

The purpose of the study is to evaluate whether a caffeine-based cream can reduce the rates of complications in patients with tissue expander based reconstruction requiring post-mastectomy radiation therapy when compared to a placebo cream.

Clinical Study Identifier: s18-00309

ClinicalTrials.gov Identifier: NCT03768492

Principal Investigators: Naamit K. Gerber, iConnect Langone.

Other Investigators: Yuliya Sundatova, Jamie P Levine, Amy N. Solan, Oren Cahlon, Benjamin Cooper, Elizabeth Wirth, Carmen A. Perez, Camille Hardy Abeloos, Mihye Choi, Caitlin Elizabeth Ryan, Jonathan Haas, Thomas B. Daniels, Gregory Edward Totero, Nolan S Karp, Olivier Maisonet, Bruce N Cronstein, Douglas K Marks.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies